Covid drug and vac­cine sales nose­dive, dent­ing bio­phar­ma rev­enue across the board

Mod­er­na re­port­ed a steep de­cline in Covid-19 vac­cine sales in the first quar­ter that mim­ic­ked a plunge in rev­enue re­port­ed by oth­er man­u­fac­tur­ers of Covid vac­cines and treat­ments.

Many of the pan­dem­ic play­ers in­clud­ing Pfiz­er, Mer­ck and Mod­er­na have warned that Covid drug and vac­cine sales would de­cline this year, es­pe­cial­ly when com­par­ing the first three months of 2023 to the same quar­ter a year ago, when there was a resur­gence in Covid cas­es due to new vari­ants.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.